FDA Grants Accelerated Approval to Asciminib for Newly Diagnosed Chronic Myeloid Leukaemia By Ogkologos - November 26, 2024 733 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ASC4FIRST study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Woman Develops Breast Cancer After Double Mastectomy, Has to Have the... May 19, 2021 El cáncer en mi comunidad: Superar los retrasos en la atención... July 6, 2023 Encorafenib, Cetuximab Combination Approved for Metastatic Colorectal Cancer May 8, 2020 Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive... July 2, 2025 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Duvelisib Sasanlimab Prolongs EFS When Combined with BCG Induction and Maintenance in... Estimate of the Global Economic Cost of the Most Prevalent Cancers... Patient Guide in Prostate Cancer Now Available in Vietnamese
